Abstract
Purpose: To evaluate the patient-reported outcomes of patients treated with commercially approved antibody-drug conjugates (ADC) reported in randomized controlled trials (RCT) published up to September 2023. Methods: A meta-analysis of 6430 patients from 12 randomized controlled trials was conducted. Results: No significant change was observed between the groups from baseline to end of treatment and end of follow-up, with a standardized mean difference of -0.08 (95% CI: -0.27–0.12) and 0.01 (95% CI: -0.11–0.12), respectively. Treatment with ADCs delayed the deterioration of patients’ clinical condition compared with treatment with non-ADCs, with a hazard ratio of 0.78 (95% CI: 0.67–0.92). Conclusion: ADCs have a good correlation with delay of clinical deterioration in patients with cancer.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2023-0253
Author contributions
T Qiu and G Shen contributed to search studies. T Qiu, G Shen, J Li, Y Xin and Y Zheng contributed to extract data. T Qiu, G Shen and J Zhao contributed to finishing the draft. All authors were involved in the revision and approval of the manuscript. T Qiu and G Shen contributed equally to this work and are joint first authors. Concept and design: T Qiu, G Shen and J Zhao. Acquisition, analysis or interpretation of data: T Qiu, J Li, Y Xin, Y Zheng, Z Zhu, C Zhang and Y Tang. Drafting of the manuscript: T Qiu and J Zhao. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: F Zhao, D Ren and H Li. Administrative, technical or material support: M Wang, Z Liu and Y Zhao. Supervision: J Zhao.
Acknowledgments
Grateful acknowledgment is made to supervisor J Zhao for his important guidance on the associated dissertation by T Qiu. In addition, he provided much on the methodology of the research, which will be valuable in the future.
Financial disclosure
This study was supported by the Central Government Guiding Local Scientific and Technological Development Funds for Qinghai Province in China. The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.